The recent identification of IL-17 secreting T cells as crucial contributors of the tissue damage in several neurological diseases raises the possibility to use Th17 cell–IL-17 pathway as a target for therapies in diseases associated with Th17 polarization. This evidence concerns the gene IL17A and nervous system disorder.